Temsirolimus, an inhibitor of mTOR, is an antineoplastic agent.
TORISEL is indicated for the treatment of advanced renal cell carcinoma.
Media Articles Related to Torisel (Temsirolimus)
Gene expression profile may identify patients with renal cell carcinoma unlikely to benefit from nivolumab
Source: Urology / Nephrology News From Medical News Today [2016.08.08]
Renal cell carcinomas positive for the protein PD-L1 from patients who did not respond to treatment with the anti-PD-1 therapeutic nivolumab (Opdivo) had significantly higher expression of genes...
Renal Cell Carcinoma
Source: MedicineNet Kidney Cancer Specialty [2016.06.29]
Title: Renal Cell Carcinoma
Category: Doctor's & Expert's views on Symptoms
Created: 6/29/2016 12:00:00 AM
Last Editorial Review: 6/29/2016 12:00:00 AM
Rethinking Cytoreductive Nephrectomy in Metastatic RCC
Source: Medscape General Surgery Headlines [2016.08.24]
Recent data suggest that cytoreductive nephrectomy may confer a significant survival advantage in metastatic renal cell carcinoma.
Published Studies Related to Torisel (Temsirolimus)
Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial. [2011.07]
BACKGROUND: Combining targeted treatments for renal cell carcinoma has been suggested as a possible method to improve treatment efficacy. We aimed to assess the potential synergistic or additive effect of the combination of bevacizumab, directed against the VEGF receptor, and temsirolimus, an mTOR inhibitor, in metastatic renal cell carcinoma... INTERPRETATION: The toxicity of the temsirolimus and bevacizumab combination was much higher than anticipated and limited treatment continuation over time. Clinical activity was low compared with the benefit expected from sequential use of each targeted therapy. This combination cannot be recommended for first-line treatment in patients with metastatic renal cell carcinoma. FUNDING: French Ministry of Health and Wyeth Pharmaceuticals. Copyright (c) 2011 Elsevier Ltd. All rights reserved.
Quality of life in patients with advanced renal cell carcinoma treated with temsirolimus or interferon-alpha. [2010.05.11]
BACKGROUND: Temsirolimus was approved in Europe as first-line treatment of poor-prognosis advanced renal cell carcinoma (advRCC) based on significant clinical benefits... CONCLUSION: Temsirolimus is associated with significantly higher EQ-5D scores compared with interferon-alpha in patients with previously untreated poor-prognosis advRCC.
Cost-effectiveness of sorafenib for second-line treatment of advanced renal cell carcinoma. [2010.01]
OBJECTIVES: To estimate the cost-effectiveness of sorafenib (Nexavar, Bayer, Leverkusen, Germany) versus best supportive care (BSC) for second-line treatment of advanced renal cell carcinoma from the perspective of the UK National Health Service... CONCLUSIONS: Sorafenib has been shown to be clinically effective compared to BSC, offering additional health benefits; however, with a cost per QALY in excess of pound70,000, it may not be regarded as a cost-effective use of resources in some health-care settings.
FDA approval summary: temsirolimus as treatment for advanced renal cell carcinoma. 
This report summarizes the U.S... Temsirolimus has demonstrated superiority in terms of OS and PFS over IFN-alpha and provides an additional treatment option for patients with advanced RCC.
Q-TWiST analysis of patients receiving temsirolimus or interferon alpha for treatment of advanced renal cell carcinoma. 
BACKGROUND AND OBJECTIVES: For patients with advanced cancers, it is important that treatment improves the quality as well as the quantity of survival. This quality-adjusted time without symptoms of progression or toxicity (Q-TWiST) analysis provides a combined measure of both the overall survival interval and the quality of survival for patients with advanced renal cell carcinoma (RCC) receiving temsirolimus, interferon (IFN)-alpha or the combination of these agents, using data from a phase III clinical trial... CONCLUSION: Temsirolimus resulted in significantly longer Q-TWiST (quality-adjusted survival) in patients with advanced RCC than IFNalpha therapy.
Clinical Trials Related to Torisel (Temsirolimus)
Torisel in Addition to Standard Chemotherapy With Radiation for Advanced Head and Neck Cancer [Withdrawn]
Patients with advanced head and neck cancer is at high risk of recurrence at the primary
site or in the neck. Part of normal treatment is to treat such patients with chemotherapy
and radiation. The chemotherapy can include Erbitux. The purpose of this study is to treat
such patients with an additional agent, Torisel. This study tests the doses of Torisel that
can be safely administered together with radiation and chemotherapy.
Sirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced Cancer [Recruiting]
The goal of this clinical research study is to find the highest tolerable dose of the
combination vorinostat given in combination with either sirolimus, everolimus or
temsirolimus that can be given to patients with advanced cancer. The safety of this drug
combination will also be studied.
Bevacizumab, Temsirolimus, Valproic Acid, Cetuximab [Recruiting]
The goal of this clinical research study is to find the highest tolerable dose of Avastin
(bevacizumab) and Torisel (temsirolimus) that can be given in combination with either
valproic acid or cetuximab to patients with advanced cancer that is refractory. The safety
of this drug combination will also be studied.
Bevacizumab is designed to block the growth of blood vessels, which may help to slow or
block the growth of cancer.
Temsirolimus is designed to block the growth of cancer cells, which may cause cancer cells
Valproic acid is an anti-seizure drug that may be able to activate tumor-fighting genes,
causing cancer cells to die.
Cetuximab is designed to block a certain protein, called EGFR, that is thought to cause
cancer cells to grow. This may cause cancer cells to die.
STORM: Temsirolimus, Rituximab and DHAP for Relapsed and Refractory Diffuse Large B-cell Lymphoma [Recruiting]
The STORM-trial consists of two parts. In the part I (dose escalation of Temsirolimus) the
primary objective is to establish a maximum tolerated dose of Temsirolimus in combination
with Rituximab and DHAP. Secondary objective is to prove ability to mobilize stem cells in
patients scheduled to high dose therapy.
In the part II (full target dose) the primary objective is to evaluate the ORR in patients
with relapsed diffuse large B cell lymphoma (DLBCL). The secondary objective is to evaluate
progression free survival (PFS), overall survival (OS) and Toxicity.
Trial of RAD001 and Neurocognition in Tuberous Sclerosis Complex (TSC) [Completed]
Tuberous Sclerosis Complex (TSC) is a multi-system disease, usually presenting with
seizures, mental retardation and autism, and exhibiting a high variability in clinical
findings both among and within families. Investigators are doing research in order to
identify possible neurocognitive benefits from treatment with RAD001 or placebo for a six
month period. There may also be potential for improvements in seizure frequency, sleep and
autistic behaviors. We hope this trial will lead to a better understanding of TSC and to
new forms of treatment, to benefit children and adults with TSC in the future.
Individuals diagnosed with TSC will be asked to participate in this study if they are
between the ages of 6 and 21 years of age and have an IQ of greater than or equal to 60.
Both males and females will be asked to participate. Additionally, to be eligible for study
participation, individuals must have been on the same seizure medication(s), if applicable,
for at least 6 months. Individuals must also be able to participate in neuropsychological
testing and meet certain medical criteria. They will need to sign an informed consent. If
enrolled in the study, participants will have a number of screening tests to help determine
if they are eligible for participation in the clinical trial. If eligible for the treatment
phase of the trial, they will be asked to take either the study drug or a placebo (pill with
no medicine), which is determined by chance.
The study involves about 9 visits, 3 of which can be done locally, over a six month period,
as well as follow-up calls with our research nurse. Study visits will vary in length.
Screening, three month and six month visits may last up to 8 hours, while all other visits
will be less than 2 hours. The study visits include blood draws, laboratory tests and
neuropsychological assessments. There is no fee to participate in this study. Some
compensation may be available for travel costs of out-of-state participants based on fund
availability. The study drug will be provided at no charge during the study.
After all study data has been analyzed, families will be informed of the overall results.
Treatment on this study may or may not improve a child's learning skills (neurocognition).
Future patients may benefit from what is learned.
Reports of Suspected Torisel (Temsirolimus) Side Effects
Disease Progression (39),
Renal Cell Carcinoma (19),
Decreased Appetite (14),
Neoplasm Malignant (9), more >>
Page last updated: 2016-08-24